Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pacific EdgeASX:PEB +4.55%35 Debt-to-Equity is 0.12 as of Mar. 2026, which is 50% above its 10-year median of 0.08. GuruFocus rates ASX:PEB with a GF Score™ of 35/100 and a GF Value™ of A$0.05 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 182 Medical Diagnostics & Research companies, Pacific Edge ranks better than 69.78% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Pacific Edge's Debt-to-Equity or its related term are showing as below:
ASX:PEB'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.08 Max: 0.12
Current: 0.12
During the past 13 years, the highest Debt-to-Equity Ratio of Pacific Edge was 0.12. The lowest was 0.01. And the median was 0.08.
ASX:PEB's Debt-to-Equity is ranked better than 69.78% of 182
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.33
vs ASX:PEB: 0.12
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Pacific Edge Debt-to-Equity Related Terms
Pacific Edge Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Pacific Edge's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:PEB vs TMO, DHR, IDXX: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Pacific Edge's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pacific Edge Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Pacific Edge's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Pacific Edge's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pacific Edge (ASX:PEB) has a Debt-to-Equity of 0.12 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pacific Edge and its competitors. This is 50% above median its historical median of 0.08. Over the past decade, Pacific Edge's Debt-to-Equity has ranged from 0.01 to 0.12. According to the industry distribution chart, Pacific Edge ranks #55 out of 182 companies in the Medical Diagnostics & Research industry, placing it in the top 30.2%.
Is Pacific Edge's Debt-to-Equity too high?
Pacific Edge's current Debt-to-Equity of 0.12 is 50% above median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 0.12. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.33. Pacific Edge's value of 0.12 is 63.6% below this industry median. Based on the distribution chart, Pacific Edge ranks #55 out of 182 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Pacific Edge has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pacific Edge's Debt-to-Equity compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Pacific Edge ranks #55 out of 182 companies for Debt-to-Equity. This puts Pacific Edge in the upper half of its industry. The industry median Debt-to-Equity is 0.33. Pacific Edge's value of 0.12 is 63.6% below this benchmark. Historically, Pacific Edge's own Debt-to-Equity has ranged from 0.01 to 0.12 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 0.33, Pacific Edge has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.33, based on 182 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pacific Edge's current Debt-to-Equity of 0.12 is 63.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Pacific Edge and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pacific Edge's current Debt-to-Equity is 0.12, which is 50% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pacific Edge stock overvalued right now?
Based on GuruFocus' analysis, Pacific Edge (ASX:PEB) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.05, compared to a current price of A$0.23 — trading 360% above its estimated fair value. The current Debt-to-Equity is 0.12, which is 50% above median its 10-year median of 0.08 and 63.6% below the Medical Diagnostics & Research industry median of 0.33. Pacific Edge's overall GF Score™ is 35/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Pacific Edge (ASX:PEB), the current Debt-to-Equity is 0.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pacific Edge (ASX:PEB) Overvalued in 2026?
Based on GuruFocus' analysis, Pacific Edge stock appears to be overvalued.
The current stock price of A$0.23 is trading 360% above its estimated GF Value™ of A$0.05.
GuruFocus considers Pacific Edge to be Significantly Overvalued.
Key valuation signals for ASX:PEB:
Debt-to-Equity: 0.12 (50% above median its 10-year median of 0.08)
GF Value™: A$0.05 vs. price of A$0.23 (360% above fair value)
Industry Position: 63.6% below the Medical Diagnostics & Research median (#55 of 182)
No single metric tells the full story. See the ASX:PEB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pacific Edge Ltd is a New Zealand-based company involved in researching, developing, and commercialising new diagnostic and prognostic tools for the early detection and management of cancers. It manages and operates the laboratories used for the detection of bladder cancer. It operates in two segments: Commercial, which includes sales, marketing, laboratory, and support operations to run the commercial businesses internationally; and Research, which is into research and development of diagnostic and prognostic products for human cancer. The commercial segment contributes to the majority of the revenue. Pacific Edge has a product in the marketplace called Cxbladder. Its geographical segments are the United States, which generates maximum revenue, New Zealand, and the Rest of the World.
35GF Score
Get the complete analysis for ASX:PEB
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PEB has been successfully added to your 
